0000849146-21-000032.txt : 20210202 0000849146-21-000032.hdr.sgml : 20210202 20210202160806 ACCESSION NUMBER: 0000849146-21-000032 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20210201 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210202 DATE AS OF CHANGE: 20210202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lifevantage Corp CENTRAL INDEX KEY: 0000849146 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841097796 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35647 FILM NUMBER: 21581486 BUSINESS ADDRESS: STREET 1: 3300 TRIUMPH BLVD STREET 2: SUITE 700 CITY: LEHI STATE: UT ZIP: 84043 BUSINESS PHONE: 801-432-9000 MAIL ADDRESS: STREET 1: 3300 TRIUMPH BLVD STREET 2: SUITE 700 CITY: LEHI STATE: UT ZIP: 84043 FORMER COMPANY: FORMER CONFORMED NAME: LIFELINE THERAPEUTICS, INC. DATE OF NAME CHANGE: 20041019 FORMER COMPANY: FORMER CONFORMED NAME: YAAK RIVER RESOURCES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ANDRAPLEX CORP DATE OF NAME CHANGE: 19920406 8-K 1 lfvn-20210201.htm 8-K lfvn-20210201
0000849146false00008491462020-11-032020-11-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ______________________________
 FORM 8-K
 ______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 1, 2021
 ______________________________
LIFEVANTAGE CORPORATION
(Exact name of registrant as specified in its charter)
______________________________
Delaware001-3564790-0224471
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)(IRS Employer
Identification No.)
3300 Triumph Blvd, Suite 700
Lehi, Utah 84043
(Address of principal executive offices, including zip code)
(801) 432-9000
(Registrant's telephone number)
_____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Common Stock, par value $0.0001LFVNThe Nasdaq Stock Market LLC
Title of each classTrading Symbol(s)Name of each exchange on which registered
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



Item 2.02.    Results of Operations and Financial Condition.
On February 2, 2021, the Company issued a press release announcing its financial results for the three and six months ended December 31, 2020. A copy of the Company’s press release is attached as Exhibit 99.1 to this report and incorporated by reference.
The information furnished in this Item 2.02 and the exhibit hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective February 1, 2021, Steven R. Fife’s title was changed from Interim President and Chief Executive Officer to President and Chief Executive Officer of LifeVantage Corporation (the “Company”). Mr. Fife also remains the Company’s Chief Financial Officer. In connection with this change in title, the Company’s Board of Directors (“Board”) also approved an increase in Mr. Fife’s base salary to $500,000 per year and set his target bonus at 70% of his annual base salary; provided, that for the fiscal year ended June 30, 2021, Mr. Fife’s target bonus will be prorated at 70% of his annual base salary beginning September 1, 2020 and 50% of his annual base salary for the period from July 1, 2020 through August 31, 2020.
Effective February 1, 2021, the Board also appointed Mr. Fife as a member of the Board to fill an existing vacancy on the Board. Mr. Fife was also appointed to the Strategic Planning Committee of the Board and will serve as the Chair of that committee. Mr. Fife will not receive any additional compensation for his service as a director.
The Company’s February 2, 2021, press release announcing the change in title for Mr. Fife and his appointment to the Board is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
There are no arrangements or understandings between Mr. Fife and any other persons pursuant to which Mr. Fife was appointed as a member of the Board. There has been no transaction since the beginning of the Company’s last fiscal year, and there is no currently proposed transaction, in excess of $120,000 in which the Company is or was a participant and in which Mr. Fife or any of his immediate family members (within the meaning of Item 404 of Regulation S-K) had or will have a direct or indirect material interest.
Item 9.01.    Financial Statements and Exhibits.
(d)    Exhibits





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:February 2, 2021By:LIFEVANTAGE CORPORATION

/s/ Steven R. Fife
Name:Steven R. Fife
Title:President, Chief Executive Officer, and Chief Financial Officer

EX-99.1 2 earningsrelease_q2fy21.htm EX-99.1 Document
logoa181a.jpg
LifeVantage Announces Financial Results for the
Second Quarter of Fiscal 2021
Revenue of $59.0 Million, Up 7.6% Sequentially
Second Quarter Adjusted EBITDA Increased 12.6%
Steven R. Fife Appointed President & CEO
Salt Lake City, UT, February 2, 2021, LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its second quarter ended December 31, 2020.
Second Quarter Fiscal 2021 Summary:
Revenue of $59.0 million, an increase of 7.6% sequentially and a decline of 3.6% from the prior year period;
Total active accounts increased 1.2% sequentially to 174,000, while declining 4.4% compared to the prior year period. The sequential growth included a 1.5% decline in distributors and a 2.9% increase in customers. Compared to the prior year period, distributors declined 1.5% and customers declined 6.1%;
Earnings per diluted share were $0.26, up 52.9% sequentially, and down 13.3% over the prior year period;
Adjusted earnings per diluted share were $0.25, consistent sequentially, and declined 19.4% compared to $0.31 in the prior year period;
Adjusted EBITDA was consistent sequentially and increased 12.6% to $6.7 million compared to the prior year period;
Repurchased 365,000, or $4.0 million, of common shares;
Strong balance sheet with $19.7 million of cash and no debt; and
Steven R. Fife appointed President & CEO; he has also joined the Board of Directors.

“We are proud to report continued earnings momentum with 31.6% adjusted operating income and 12.6% adjusted EBITDA growth while we saw modest declines in revenue of 3.6% compared to the prior year period, the highest quarterly revenue in the company’s history and 7.6% sequential revenue growth over the first quarter of fiscal 2021. We saw positive momentum from our virtual convention held in October which reached an estimated 20,000 participants in 18 countries. At the convention we launched limited time expanded Axio flavor offerings, featuring 6 new flavors and a new digital tool called ITT, aimed at standardizing the education and training of new customers and distributors. We saw strong adoption of the ITT system and a successful response to promotions launched in the quarter driving enrollments,” stated LifeVantage Chief Executive Officer and Chief Financial Officer, Steve Fife.

“As we look to the second half of fiscal 2021 we are excited for the initiatives we have in place, including the timely addition of new products to our portfolio in Q3 and Q4, innovative digital tools to aid our Distributors in customer retention, and the expansion of our virtual training platforms to develop the leadership of our Distributor base. We remain on track to meet our 2021 expectations and are confident in our business model as we continue to execute alongside the current pandemic. We are proud of the LifeVantage team and are focused on driving growth while delivering shareholder value.”




logoa181a.jpg
Second Quarter Fiscal 2021 Results
For the second fiscal quarter ended December 31, 2020, the Company reported revenue of $59.0 million, a 3.6% decrease compared to the second quarter of fiscal 2020. Revenue in the Americas for the second quarter of fiscal 2021 decreased 5.4% compared to the second quarter of fiscal 2020 and revenue in the Asia/Pacific & Europe region increased 1.0% compared to the second quarter of fiscal 2020. Revenue for the second quarter of fiscal 2021 was positively impacted $0.7 million, or 1.2%, by foreign currency fluctuations associated with revenue generated in international markets when compared to the second quarter of fiscal 2020.
Gross profit for the second quarter of fiscal 2021 was $48.8 million, or 82.7% of revenue, compared to $51.0 million, or 83.3% of revenue, for the same period in fiscal 2020. The decrease in gross margin as a percentage of revenue is primarily due to increased shipping to customer expenses and shifts in geographic and product sales mix.
Commissions and incentives expense for the second quarter of fiscal 2021 was $27.2 million, or 46.0% of revenue, compared to $29.2 million, or 47.7% of revenue, for the same period in fiscal 2020. The decrease in commissions and incentives expense as a percentage of revenue is due mainly to the timing and magnitude of investments in our promotional and incentive programs and our red carpet program.
Selling, general and administrative (SG&A) expense for the second quarter of fiscal 2021 was $16.2 million, or 27.5% of revenue, compared to $18.1 million, or 29.6% of revenue, for the same period in fiscal 2020. Adjusted for nonrecurring expenses and recoveries, which are detailed in the GAAP to non-GAAP reconciliation tables included at the end of this press release, adjusted non-GAAP SG&A expenses for the second quarter of fiscal 2021 were $16.6 million, or 28.1% of revenue, compared to adjusted non-GAAP SG&A expenses for the second quarter of fiscal 2020 of $17.9 million, or 29.3% of revenue. The year over year decrease in non-GAAP SG&A expenses was primarily due to decreased event and travel expenses as well as decreased stock and incentive compensation expenses partially due to the departure of executives.

Operating income for the second quarter of fiscal 2021 was $5.4 million, or 9.2% of revenue, compared to $3.6 million, or 6.0% of revenue, for the second quarter of fiscal 2020. Accounting for non-GAAP adjustments noted previously, adjusted non-GAAP operating income for the second quarter of fiscal 2021 was $5.1 million, or 8.6% of revenue, compared to $3.9 million, or 6.3% of revenue, for the second quarter of fiscal 2020.
Net income for the second quarter of fiscal 2021 was $3.8 million, or $0.26 per diluted share. This compares to net income for the second quarter of fiscal 2020 of $4.3 million, or $0.30 per diluted share. Accounting for the non-GAAP adjustments noted previously, net of tax, adjusted non-GAAP net income for the second quarter of fiscal 2021 declined 22.1% year over year, to $3.6 million, or $0.25 per diluted share. Accounting for the non-GAAP adjustments noted previously, net of tax, adjusted non-GAAP net income for the second quarter of fiscal 2020 was $4.6 million, or $0.31 per diluted share. The Company’s effective tax rate increased to 31.6% in the second fiscal quarter of 2021 compared to an effective tax benefit of (24.5%) in the prior year period. The increase in the current year tax rate negatively impacted adjusted earnings per share by approximately $0.20.

Adjusted EBITDA increased 12.6% to $6.7 million for the second quarter of fiscal 2021, compared to $6.0 million for the comparable period in fiscal 2020.
Fiscal 2021 First Six Month Results
For the first six months of fiscal 2021, the Company reported revenue of $113.8 million, a decrease of 3.1% as compared to $117.5 million for the first six months of fiscal 2020. In the first six months of fiscal 2021, revenue in the Americas decreased 4.6% and revenue in Asia/Pacific & Europe increased 0.8%. Revenue for the first six months of fiscal 2021 was positively impacted $0.9 million, or 0.8%, by foreign currency fluctuations associated with revenue generated in international markets when compared to the first six months of fiscal 2020.
Gross profit for the first six months of fiscal 2021 was $94.2 million, or 82.8% of revenue, compared to $98.0 million, or 83.5% of revenue, for the first six months of fiscal 2020. The decrease in gross margin as a percentage of revenue is primarily due to increased shipping expenses, decreased fee revenues as a result of fewer distributor meetings in conjunction with the COVID-19 pandemic, as well as shifts in geographic and product sales mix.


logoa181a.jpg

Commissions and incentives expense for the first six months of fiscal 2021 was $52.8 million, or 46.4% of revenue, compared to $56.0 million, or 47.7% of revenue, for the same period in fiscal 2020. Commissions and incentives expense as a percentage of revenue decreased during the comparable periods due to the timing and magnitude of investments in our promotional and incentive programs and our red carpet program, all of which have been limited as a result of COVID-19 restrictions and mandates.

SG&A expense for the first six months of fiscal 2021 was $32.5 million, or 28.6% of revenue, compared to $35.8 million, or 30.5% of revenue, for the same period in fiscal 2020. Adjusted for nonrecurring expenses, which are detailed in the GAAP to non-GAAP reconciliation tables included at the end of this press release, adjusted non-GAAP SG&A expenses for the first six months of fiscal 2021 were $31.3 million, or 27.5% of revenue, compared to adjusted non-GAAP SG&A expenses for the first six months of fiscal 2020 of $35.4 million, or 30.1% of revenue. The year over year decrease in non-GAAP SG&A expenses was primarily due to the cancellation of in-person events and decreased travel expenses related to the restrictions associated with the COVID-19 pandemic, as well as lower stock and incentive compensation expenses due in part to the departure of executives.

Operating income for the first six months of fiscal 2021 was $8.9 million, or 7.9% of revenue, compared to $6.2 million, or 5.3% of revenue, for the first six months of fiscal 2020. Accounting for non-GAAP adjustments noted previously, adjusted non-GAAP operating income for the first six months of fiscal 2021 was $10.2 million, or 8.9% of revenue, compared to $6.7 million, or 5.7% of revenue, for the same period in fiscal 2020.
Net income for the first six months of fiscal 2021 was $6.3 million, or $0.43 per diluted share compared to $6.1 million, or $0.42 per diluted share for the first six months ended 2020. Accounting for the non-GAAP adjustments noted previously, net of tax, adjusted non-GAAP net income for the first six months of fiscal 2021 increased 10.8% to $7.2 million, or $0.49 per diluted share. This compares to adjusted non-GAAP net income for the first six months of fiscal 2020 of $6.5 million, or $0.45 per diluted share. On a non-GAAP basis, the Company’s effective tax rate increased to 29.3% in the first half of fiscal 2021 compared to an effective tax benefit of (2.3%) in the prior year period. The increase in the current year tax rate negatively impacted adjusted earnings per share by approximately $0.22.

Adjusted EBITDA increased 25.8% to $13.4 million for the first six months of fiscal 2021, compared to $10.7 million for the comparable period in fiscal 2020.
Balance Sheet & Liquidity
The Company generated $4.8 million of cash from operations during the first six months of fiscal 2021 compared to $5.8 million in the same period in fiscal 2020. The Company's cash and cash equivalents at December 31, 2020 were $19.7 million, compared to $22.1 million at June 30, 2020. The Company had no debt outstanding at December 31, 2020 and June 30, 2020, respectively. During the second quarter of fiscal 2021, the Company repurchased approximately 365,000 common shares for $4.0 million under its share repurchase program.
Management Changes
Also announced on February 2, 2021, the Company named Steven R. Fife as President and Chief Executive Officer. Mr. Fife’s appointment is effective immediately as he has been serving as Interim Chief Executive Officer since September, 2020. He has also joined the Board of Directors.

Additionally, the Company announced it has initiated an executive search to identify a new Chief Financial Officer. Mr. Fife will continue to serve in this role until a replacement is established.

Fiscal Year 2021 Guidance
The Company is reiterating its outlook for fiscal 2021 adjusted net income and adjusted EBITDA, and now anticipates fiscal 2021 revenue to be at the low end of our prior revenue guidance range of approximately $240 million to $251 million for fiscal year 2021, reflecting the timing of our product and geographic launches. The Company expects to generate adjusted EBITDA of $25 million to $27 million, with adjusted earnings per share in


logoa181a.jpg
the range of $0.87 to $0.91, which assumes a full year tax rate of approximately 30%. The Company's guidance for adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per diluted share excludes any non-operating or non-recurring expenses that may materialize during fiscal 2021. This guidance reflects the current trends in the business and the Company’s current view as to the impact of the COVID-19 pandemic on its business. However, the impact of the COVID-19 pandemic continues to evolve and actual results could be adversely affected by further deterioration to the global economic and operating environments as a result of future COVID-19 developments. The Company is not providing guidance for GAAP earnings per diluted share for fiscal 2021 due to the potential occurrence of one or more non-operating, one-time expenses, which the Company does not believe it can reliably predict.
Conference Call Information
The Company will hold an investor conference call today at 2:30 p.m. MST (4:30 p.m. EST). Investors interested in participating in the live call can dial (877) 705-6003 from the U.S. International callers can dial (201) 493-6725. A telephone replay will be available approximately two hours after the call concludes and will be available through Tuesday, February 9, 2021, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13714685, or (412) 317-6671 from international locations, and entering confirmation code 1374685.
There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at http://investor.lifevantage.com/events-and-presentations or directly at
http://public.viavid.com/index.php?id=142898.The webcast will be archived for approximately 30 days.

About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics, a new science dedicated to biohacking the human aging code. The Company engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and skin and hair care products, including its Protandim® product line, LifeVantage® Omega+ and ProBio dietary supplements, the TrueScience® line of Nrf2 infused skin care and hair care products, Petandim® for Dogs, Axio® smart energy drink mixes, and the PhysIQ™ weight management system. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah. For more information, visit www.lifevantage.com.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, and expected financial performance. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments as a result of future COVID-19 developments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.



logoa181a.jpg
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.

Investor Relations Contacts:

Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com


logoa181a.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands, except per share data)December 31, 2020June 30, 2020
ASSETS
Current assets
Cash and cash equivalents$19,726 $22,138 
Accounts receivable3,269 2,610 
Income tax receivable536 — 
Inventory, net14,712 13,888 
Prepaid expenses and other4,216 5,232 
Total current assets42,459 43,868 
Property and equipment, net11,027 7,170 
Right-of-use assets14,037 956 
Intangible assets, net785 851 
Deferred income tax asset1,866 2,164 
Equity securities2,205 2,205 
Other long-term assets2,047 1,663 
TOTAL ASSETS$74,426 $58,877 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable$5,155 $3,521 
Commissions payable8,039 9,219 
Income tax payable651 784 
Lease liabilities2,049 1,184 
Other accrued expenses6,560 10,311 
Total current liabilities22,454 25,019 
Lease liabilities15,409 — 
Other long-term liabilities1,047 604 
Total liabilities38,910 25,623 
Commitments and contingencies
Stockholders' equity
Preferred stock — par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding— — 
Common stock — par value $0.0001 per share, 40,000 shares authorized and 14,151 and 14,313 issued and outstanding as of December 31, 2020 and June 30, 2020, respectively
Additional paid-in capital128,011 126,416 
Accumulated deficit(93,044)(93,307)
Accumulated other comprehensive income548 144 
Total stockholders’ equity35,516 33,254 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$74,426 $58,877 



logoa181a.jpg


LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
Three Months Ended December 31,Six Months Ended December 31,
(In thousands, except per share data)2020201920202019
Revenue, net$59,007 $61,242 $113,835 $117,470 
Cost of sales10,189 10,230 19,587 19,421 
Gross profit48,818 51,012 94,248 98,049 
Operating expenses:
Commissions and incentives27,151 29,235 52,785 56,009 
Selling, general and administrative16,218 18,131 32,517 35,817 
Total operating expenses43,369 47,366 85,302 91,826 
Operating income5,449 3,646 8,946 6,223 
Other income (expense):
Interest expense, net(9)(41)(15)(89)
Other income (expense), net133 (148)(8)(228)
Total other income (expense)124 (189)(23)(317)
Income before income taxes5,573 3,457 8,923 5,906 
Income tax (expense) benefit(1,761)846 (2,660)158 
Net income$3,812 $4,303 $6,263 $6,064 
Net income per share:
Basic$0.27 $0.31 $0.44 $0.44 
Diluted$0.26 $0.30 $0.43 $0.42 
Weighted-average shares outstanding:
Basic14,193 13,902 14,225 13,908 
Diluted14,439 14,562 14,547 14,515 



logoa181a.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Revenue by Region
(unaudited)
Three Months Ended December 31,Six Months Ended December 31,
(In thousands)2020201920202019
Americas$41,883 71 %$44,284 72 %$80,559 71 %$84,465 72 %
Asia/Pacific & Europe17,124 29 %16,958 28 %33,276 29 %33,005 28 %
Total$59,007 100 %$61,242 100 %$113,835 100 %$117,470 100 %
Active Accounts
(unaudited)
As of December 31,
20202019Change from Prior YearPercent Change
Active Independent Distributors (1)
    Americas45,000 67 %46,000 68 %(1,000)(2.2)%
    Asia/Pacific & Europe22,000 33 %22,000 32 %— — %
        Total Active Independent Distributors67,000 100 %68,000 100 %(1,000)(1.5)%
Active Customers (2)
    Americas82,000 77 %89,000 78 %(7,000)(7.9)%
    Asia/Pacific & Europe25,000 23 %25,000 22 %— — %
        Total Active Customers107,000 100 %114,000 100 %(7,000)(6.1)%
Active Accounts (3)
    Americas127,000 73 %135,000 74 %(8,000)(5.9)%
    Asia/Pacific & Europe47,000 27 %47,000 26 %— — %
        Total Active Accounts174,000 100 %182,000 100 %(8,000)(4.4)%
(1) Active Independent Distributors have purchased product in the prior three months for retail or personal consumption.
(2) Active Customers have purchased product in the prior three months for personal consumption only.
(3) Total Active Accounts is the sum of Active Independent Distributor accounts and Active Customer accounts.



logoa181a.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA
(Unaudited)
Three Months Ended December 31,Six Months Ended December 31,
(In thousands)2020201920202019
GAAP Net income$3,812 $4,303 $6,263 $6,064 
Interest Expense41 15 89 
Provision for income taxes1,761 (846)2,660 (158)
Depreciation and amortization(1)
651 709 1,782 1,245 
Non-GAAP EBITDA:6,233 4,207 10,720 7,240 
Adjustments:
Stock compensation expense983 1,547 1,447 2,918 
Other (income) expense, net(133)148 228 
Other adjustments(2)
(377)55 1,253 286 
Total adjustments473 1,750 2,708 3,432 
Non-GAAP Adjusted EBITDA$6,706 $5,957 $13,428 $10,672 
(1) Includes $101,000 of accelerated depreciation related to a change in lease term and $335,000 leasehold depreciation for the six months ended December 31, 2020. Includes $152,000 of accelerated depreciation related to a change in lease term for the three and six months ended December 31, 2019.
(2) Other adjustments breakout:
      Class-action lawsuit (recoveries) expenses$(396)$55 $213 $187 
      Executive team severance expenses, net19 — 524 — 
      Executive team recruiting and transition expenses— — 21 — 
      Lease abandonment— — 495 — 
      Other nonrecurring legal and accounting expenses— — — 99 
Total adjustments$(377)$55 $1,253 $286 



logoa181a.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS
(Unaudited)
Three Months Ended December 31,Six Months Ended December 31,
(In thousands)2020201920202019
GAAP Net income$3,812 $4,303 $6,263 $6,064 
Adjustments:
Executive team severance expenses, net(1)
19 — 74 — 
Executive team recruiting and transition expenses— — 21 — 
Class-action lawsuit (recoveries) expenses(396)55 213 187 
Other nonrecurring legal and accounting expenses— — — 99 
Accelerated depreciation related to change in lease term— 152 101 152 
Lease abandonment(2)
— — 830 — 
Tax impact of adjustments119 51 (314)(14)
Total adjustments, net of tax(258)258 925 424 
Non-GAAP Net Income:$3,554 $4,561 $7,188 $6,488 
Three Months Ended December 31,Six Months Ended December 31,
2020201920202019
Diluted earnings per share, as reported$0.26 $0.30 $0.43 $0.42 
Total adjustments, net of tax(0.02)0.02 0.06 0.03 
Non-GAAP adjusted diluted earnings per share(3)
$0.25 $0.31 $0.49 $0.45 
(1) Net of $450,000 of compensation expense benefit related to unvested stock award reversals.
(2) Includes remaining lease rent expense of $495,000 and leasehold depreciation of $335,000 for the six months ended December 31, 2020.
(3) May not add due to rounding.


EX-99.2 3 exhibit992pressrelease.htm EX-99.2 Document

image1a.jpg

LifeVantage Announces Appointment of Chief Executive Officer

Steven R. Fife Named President, CEO & Director

Salt Lake City, UT, February 2, 2021, (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) announced today that its Board of Directors has named Steven Fife as President and Chief Executive Officer. Mr. Fife’s appointment is effective immediately as he has been serving as Interim Chief Executive Officer since September, 2020. He also joins the Board of Directors.

“Steve is a highly experienced and accomplished executive with a deep understanding of our business and a clear vision for the future,” said Garry Mauro, the Company’s Chairman of the Board. Mauro continued, “Steve has been instrumental in the growth and success of the Company since joining as CFO in 2017. As we conducted our search over the past several months it became clear that he was the ideal candidate to lead the Company as CEO going forward.”

Mr. Fife commented, "I am incredibly excited about the opportunity for LifeVantage. Our unique portfolio of products is firmly aligned with consumers’ desire for healthier lifestyles. We have an outstanding team and have a built a strong platform to support significant growth.”

Steven Fife has more than three decades of financial and leadership experience. He joined LifeVantage as Chief Financial Officer in March 2017 and was also appointed Interim Chief Executive Officer in September 2020. Prior to joining LifeVantage, Mr. Fife was Chief Financial Officer and Chief Operating Officer at Evidera, Inc., a private equity sponsored professional services firm that provides outcomes research, market access, data analytics and epidemiology services to pharmaceutical companies. Prior to Evidera, Mr. Fife was Chief Financial Officer at several public companies including Active Power and LECG, and held senior finance positions at Gilead Sciences and JDS Uniphase. Steve’s leadership experience encompasses domestic and international businesses and he has a track record of driving growth, profitability and operational excellence.

Additionally, the Company announced it has initiated an executive search to identify a new Chief Financial Officer. Mr. Fife will continue to serve in this role until a replacement is established.

About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics, a new science dedicated to biohacking the human aging code. The Company engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and skin and hair care products, including its Protandim® product line, LifeVantage® Omega+ and ProBio dietary supplements, the TrueScience® line of Nrf2 infused skin care and hair care products, Petandim® for Dogs, Axio® smart energy drink mixes, and the PhysIQweight management system. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah. For more information, visit www.lifevantage.com.

Investor Relations Contact:

Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com

EX-101.SCH 4 lfvn-20210201.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 lfvn-20210201_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 lfvn-20210201_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 lfvn-20210201_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover [Abstract] Cover [Abstract] Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 8 lfvn-20210201_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 9 image1a.jpg begin 644 image1a.jpg MB5!.1PT*&@H -24A$4@ 3( _" 8 !C+T2O @ $E$051X >U= M!WA55;:^5WV6<134<71&G>=TGSZ?CD/NO0D@4@4;%I11<5!Q$!4$D=1[DY"$ MWCM([R6]D806((0:2B@)12"DAR2DDQ[^]ZU][KDY[9:$5#GG^\YWRCV[K7/W M?]9>^U]K:Z!NJ@14":@2Z.02T'3R^JO55R6@2D"5 %0@4_\$J@14"71Z";0Y MD"5?RL:IB]DX=2D71665G5Z :@-4":@2:'\)M!F0'3Q]#8.^7P6MS@-:O1>T M>B/^.'@:)JW:C8K*FO:7A%H#50*J!#JM!%H=R#*OEV#DY&!H=>[0=@^ ULD= MC_7QP4,]O:!U\8/6V1?/?S0;F^).=5HAJA57):!*H'TET&I =K.J!I-7[<'C M_?TXP#+X0#]\(6(/GD=I114R\HIA6AJ+!WN:H'4)@-;@C=='K\#1WNC[MU'OAN1CAR"\MDSZHW5 FH$E EH"2!%@6RI)0,#!J[&EH#:5G^ M>+"'$1/F1>/ZC7*ELD7W8@]=@&[X0C;4I+1/ONZ/Z>OVHK*Z5O2<>J%*0)6 M*@&I!%H$R++S2S%F1CCNT9OM8#HO?.2Y$1>NY4O+LWE=W]" 18$'\=2@ :$ M6N>)>.F3N0C9<\9F.O5'50*J!.YL"=P6D%55UV+AMH/XW4 >>'SA].\%(.WJ M=C8:5OXP.Q(/=#=R@*8W8N"8E4A*S;R=;-6TJ@14"?Q")=!L( O=>PXO_FNV M>2CHA]\/FH3Y6Q-16U??8J(Z=R47'[BM8U0-FA"XU]D+W\\,!VF =_)6UW + MA;5 84T#"FMNH:Q6;GN\D^6CMOW.DT"3@>QX:B;>&;_&#"[^N%OO@3$SPY%3 MT'K@$I60RMG/##Y,0R/07!IR&'4M")J=X=7ONUZ-[TX6XY\[OWX;<#_,W\,Q_\<]@\A.T]:Y%(PLFKB#IP'E&)%Y!Z M-<]ROZ.='+U1@\2":H>K551=C\$'BZ )N0[-]G)HP@J@"Z@.J!'YI M$K )9+&'SN/5D:&=(_U]<7L30FHJ:UK=SDD)J?AK1_60*OS8L!%+D\, MW+I-@)9VY@IE1&1"2KO7E2IPJ:P.#X7GMEJ)MI: 52!SFQ\%K<'(M)[_,GAB MU)10I&7?:.OZV2TO:,\9/-#="UHG-P[ >""CH\&$ =\MMYN'](&W8W_ZX601-#$5T&P6 E(: ZGO3RC+=?_U*FXXR0.54!N+N $-#2FW MID,3F 5-="DT\<#D%AA:%I=5XE)Z 7O?],[Y_7)F(_ M$*&9-Y%24HN#^55P/56$?R24(^#<[=O("$R>'."'1_OXXM'>WI:]:Q\_#!S= M] ^#4N.^F1J"KGW]+7FS)A"QNK-L9#M^_L,9>+3OQ,:V]/%ALDM, MOMI9FM'IZZD(9(;/%S![V. ?U^#6K5L=NI'DM_DT$6C)Q4D(8DPC\\9'[NN; M7/^7XW*@V5YF-J:303T'FAU5^/A009/SXA-,2REA>BU5=?7(JVH9^LN@[U> ",GDY&_92<8ZC]L&FORB"CS2 MVX>;^1;F;Z )G+FH[@"F"_Z]V3OF%9;A-WTE;2&SALX3\4D_VTNN_MY"$I ! M&:G)%)V"HE)$'^@8]B5[;5T<>)#CLU%X()H$Z/8CZR3W.7OB[.5<>\EEOSOM MR&%:CPATHDOQV>'F UE133V<=E^'9F2F0D4TL M) \)UUMF>"=KN.!&:/Q9#FB8/,UV1_9Q\,&/\R(%3S;]=&784'#LVC; MP:9GV(XIR/WN]P/].)LLWQXG5V;JV'?B,V9L,W@C?=Z[3 M2&-YR&$\-V06[B=[FIZN)XMQW.Q>?AK3!Z,Y\J1 M4VE]XD2FD9&M+# 3*:76)P=:ZH61C^M?!D^5:[HZ3_QI\!14U5BOMZTZD(;? M_]N?H-6;Q!HTA7?JZ^N07ZZM_-OZ-Q7(VEKBRN7)@.S(V71.JS%XBSA:RLD[ MUMVJFEJ,FA(";8^I<)T7U>S*M1:0\16JJK^%RGK[0W9E(,M"LHU93KZ,ECAZ M+HKA9H1Y38,_ZKVP/3&U6460_>U> PU7)9,S!F]\:MK4K#S;,Y$*9.TI_<:R MVQS(5E\I0X_$K@?8& MLO-IUW&_B\*,L,&$8:;-CC9#]-S,=7OEX.CDBGN<3=A[O/,-Q50@$[W>=KMH M4R"+SZOB;$-$%=A5A][Q+<^^'S$&CL9\-+;.0WLP/ +ED M%M7>0E%- SO6--C7"ON.6F:VE0GL9$X>Z-K+V*QAX"N?SN%"G?/:'1UU7OC? MCV:TR\02#76);D+K1Q2520X8CS]@F2V-0.?'"H0IT\NA6MR,0H5_"SSJ^NQ^EHEQIPNQ__%YN#1 M\!P\&I+)CB_&Y+#[*],JD6]EPF%3[$EEP[S>A+61Q_C_D4-'BOY+OKDBXC(! MF=Z$.1OW6_(H*KV)<;/",6YV).A]*NZS(^&U.*9)$5&(GY9R-1\_A1[&N#E1 M^&Y:*+I_N1"/]_-A]CF:Y"([W1/])^+=']>P9Z(3+Z#\IG5W,D4@8R#MBB%N MZY3KSK=I=B1^F!.%K.N-E!DJR[@X%N-F1UE/.SL2;O.C?);MP*>F M+?C]0'\N_[X^;")QT)B5K&W[3EQ1#+9J^2,TX:3-@.Q ?A7N(A]!(;DSNA0? M'FR:@.RUK2,#V6.A&=#LKN>H'43OL+>3!X"(0&MV3XHL;DQ+/I;[ -W.7%!4 M#'XKKFF ;VHYGHHM@(8]7PY-:+[81Y.NR7JK<\9^^ID\.F"B> ME:..:C"AS]=-X^B-GQ,!+3G^LXYNUO"8K0,WHO/#=D)C;'G>1%*SI:!S(":,K#6OV]H>T^"<^^/5FT^,Z6'2UVVCFBAJY]DIEP&1$=?=A[_X^ M@SOZCUZ)^5L/@,C,UK93%[/P+Z_-^"^#A[G^)NZ_(\R?EZW.$RY?+L'^%IC= M;3,@FWF^U$SN%##;@TD[2$=A=0VK18[IT$84(2BC MD0V?45&+EW<70!-[DV/_.U(.44*B2S'T8(%L(H)")\D!R(W-$),=S9&-9D'_ M0/ZZQ+$2 IG!A$^-8B._TV?SY,-981KA.5$=G'WQTL=SD5,@#X_^+\\-##!8 MU&)6-M%S:!<,E6V>NW)@IS=AWN8$65-M IG-?.ECX(TE08=$>0[X5F$H;S4? M5_9>GG@] !>O67\/#0VW,'YN%.[KSODA,^"VFJ>27#@Z"0-6)S=%.5,CUF\_ MC@=ZF %2.IFC6![5WX3[NAL1<9L,B38!LKI;0+>=>5S4!F&G(NUL6Q;VYUM7 MW45OV8&+3@EDQ ]3VH6R$IZ;AY@L35@!_A2=C3HS0S:KLA[/Q5&4C+)&VQJ? M-C ;FL@B;B?MF,KD?Z,CO8^X2HPY+N;+'3N7@;M(2Y$"@,$' 2MW.?!6P*@\ M3/L1_:%=&;UCU]%+ECP.G4[#W09>2Z(.)-E%Z06=SF4B/O;:".JTPFVX[Q9. M,["6CMT7E"%M(Y^.- J]"4&[3PNS9W9"&8^,3\/RXH%3'7/;U$=>;+F;\E@?OX2#]45 81J4D+H]W*[P_T],%NP?^ S]?18ZL!65EM M/8(R*_'AP0*\0B!&_H!;TL4=ASI/8!:ZAF3@C8/%<#]3AI/%M^>?UBF!C _) M$YS#HF)PX7ER.#]*(=#PY\+GXZHPX13G.E51UX 7B41+PTW+D#2-7M]W'?\@[P7RU0PO%#S+O0^ZMU= NB6,[#EBD5Q+TGOAA0]G@$(L MV=O(PX)I17SG87]P,O+/1%5UXU!E^,2M'+F9ONA*.]\AA/G0N9,[[M&YXJK$ M'_ASRH^&:*+G?^2&DVSH9C(/+C""I*P*$WXN_O3Q,-K6QJ9*S^ L\( MX?#*V1@^6E^6 MVJ\@:RI+*@,K0$8>#$S;DX(47>N\\+?WIF'@F!5L)WL9DR_)0OA.]";\_?T9 M-NV1HL9)+EH%R#:GE>//L?F<;8:,^_3UYSNA[)C&V6W(CA-=BGM"[@Z32PZF MK8W'@-$KY3.?U"D,WIB]89_H+ZX(9$[NS*WMVVEA,"V)!9' ^?+61B5A\(_K MS'8=J69"&J0'=AV]:"E#$2%+,Q8MQ=OC5O# :\49 PF3%HEUH[71!XSFP0D[3"#XBO#YF/B3W%( MOI0C*O-82@;C8;)@#,)R%("LLJH6SP^9(?]OZ(UX:M DA,2?8\L_\@++NU&. M!5L3F6^J;(AK\ ;)OSE;BP/9QK0*SCF:OO26#F4CAI;T&8K5%5>%Y[9G6YU) ML]70S@5D7'RQS)O*H,VT*^%'@( O, L_E\NU5O*Q[!)"P)?7*/=M&;@K+!\K M+\MM1[P,28O[6TRNV*A!R<6<30E< MB"AA1R:P=/;!K(V-8&D5R)S<<"PE79)KRUQ^,S54H>TFO#UNM:4 6E?VK^^1 M9P:Y[0F&X 1B.@_XK=AE5Y-^@B9YA)J3 I"MCTZ2:[PZ#SSUYF2<3[-.K]JP M_;AB&]Z?H#Q$MC3,RDF+ UFWN%S.J&\9VC0!Q'A0(QM09#'.E31V)"OUE]WN MC$!VOE2YG4TAQ*Z\PLT^-GX\TMALY-!$^[/"1%+64%B@K8)W%5V&-5DJ0XI_VM_U]D5]D?G'98:V@*RUO*UC-R?(O\P&$SXP'6=I5ZT$#8; MB@I!C&FM)AG86Q()3FBV^O%^-,P5# $E0$9#5]F[)6U4YX7H _8]/WI^M5@L M7YT['N_KBUR%21M!U11/6QS(UO =2JA)\ #ER)$H!W%5^'.4=6=JQ9:8;]ZI M0$8T%A:3C)?QMDS<'Y&/9 =LCA=+:Z$E&Z9YJ,O ,+H4BR^)-3E:K^%>%[*I M2(8J>I-5>@+1'RB>G;:;T"6)_NQ&4(=L[L8_);'R.V#0= 3):[:Q+ M+[.-D0=,O1<,P^?SXK%Y9%HO34+P:9FMSI7%PK.94.''%@ MOL%Y>"8\@P6')$^ ])OU5O8Z'"FHQJ/!&9P]C4\?4:08[4,W?+[\2Z^G )8_ M*;X3[V6QB;<2\O%"+#]K*1BZ\!UF6R8>#$I'GP/%^#ZY#(<*[?^YK36&[M^)0':A MK([16*1TBKNV7L-#0>EX*)CV#.4]*!T/!V?@;D;I$+R?\$*0SZET6Q9R&%J] M1$MQAA!#N'"C88>-*LIBQ5G\(;W$NL=BHB;OC_MPGNN&[CT_!?;WM%@ M0EL 67\!:+-;V?WPRIU%;<:#MPJ$E14:6#2WU7MA]S+$8:8X M&6FU,J#O-@$/N'B@RZLF/-S3:'7O\JH1]SM+O#S,DR1'SS;=MMAJ0";\0U?6 MW<++9#N3#C?-QNM=>8[[M@GS53J_$X&,U@/0TH=!MCA)NIG)3RLNV=D)R/B/ M"QW#"]%- &W$O.>GS;6=>!SR? M3$B1D SMF?S%-C)K0!9WN''&52I_X;4C0+::S8I*/FI4%_:^K-!.A!04>J?\ MN^/3=7-%AP4R$M"TU!(S25/ [ _*0=?@=-RHL<]#$@K9UKD*9+Q6E<817FG( MSI-@FW+<58?GHK,41?V%$C=+[X67_C5;-!,V:DJP_(NM-V+0F.6R"+=D?WOF MK:EFXJ:PHQ*SWDRF%!ZELZ?FSMP9-3*BG#PY<#(G*U'GYKT*).TG<"8#F9FC)WQ7CIX3?T]OPJ'330^MWR8:&?4&XDEI*6RSQ*#\ M_@'KKA6*O;/J>4X-] E*L4.Q[ MCOUL'BZ* >XC%N-CSXV@*,A\ MVT?/"%,8KHLULCY*44L,1DQ?MUVL7C@#9J@CBJ4DT,ITGAGEO9IXH; T9/RGI*2/K]7@GJLCCLKS[V! 1D-K>QM;Z$<*!D[NZ/*:CU7_ MP^V)Y^4 (M'(/O)8+Y>/W@LO?C33H7!)C@"9XM#2X(VO)]OF%=J327-^;U,@ MVY%3R=G)",QVUJ+'+KF=I#F-$*:Y$X&,VO_> <[I6VCGTD858]X%>40+H;R: M>SYE]1YY9])YX)DW E@TAP_B.6!-I?%\$1($O/+<*O>TKLI0R$O5MTZ4BRRY)G@ZVM38&,*K+D4BFZ M[2_#H,0BI"DPU&U5UI'?6@W(MI=AQ%'E9=LY,O]5&OW";)QO"4+LBLME MYEAOO(WL&J-3=(G,MSI$=*3>UIZA/U=76@E)2)BDCN+DQMR.?O>Z'V>@Y[4L M)S?+(%DJR M'.JQ01&4HFPL_.,(D-'[^4T_8N9+HHTXN>->%R.(.F%O^VU_^\Q^XHS)/BAZ M+^@_7X3"$C&AVEYYTM\;;MW"3R&',6?3?N:)02Y82O\?2M?F0":M;$M?MQJ0 MA1>RB+;1V96(S+II9Z]$6%8E*!(%O[4VD%$HI"?")5PR\JX(R\>O0G,P+;44 MI10BUL96?^L6+I35P_U+8$R+A@BR8;6DE' ;*Z^GJPY1.E'@!L&#V5^3$*&UU160VRB_$;N>3( M-3(CW!=$\X_(CHX &27R6+B=4%CZ6 5EBUDJRCQ;]MU7C0+=?W= MM!#^5I./BC'[-YOI#2Q"12YSQ"9G;,6=_!UC*K ^K=%MI[6!C!I)PT@6*%%( MI2 P(\?QB"(\%9Z);T^6L!GDPP75;!$3 F;3&8H\4H)7XG(8Z&EV5./AX'3< MK+,-?!1VA>.("8W^!:W+H-F)3[ G%=S%N=H0<$!DWS80-,3H9EF MP_B.0\=V&%I2@RCBJ0R,J#XZ#]"2A(/'KV:@0HL2/_7&9 P>O\8BAQ_G1BJV MG;PAE@0?%D7:X!,Y8B.C9VEX^)=WIRO7C0"*;'-.;FPQ9EJ0F=\9?8+9[23O M40'("%2?)@-YC42S3 D]=S&;KHI)=U&-A++Z>'-RX+FWW21@U M-9AO)I:''F;DV/&S(YAF1M&*R?:J1,^0 =FUG"(\:E[7LKDKY5AJT@XG'] 7 MKL=DT-1_\?R(5X9"?.9S*S@5:O ML$@V?=0(T*C]C#9B_M"1,SLO$T:EH>=,&#LKG*\Z-L:>P)%SZ?!:% .B_!#C MGX;$5[.XL%66!Y6&EO2C[M_SV$KC0YJQ2K/0V)HP9ZY76!6)_^/S1X,WB_]N+0^Z/WI:*/O/L0[,IV-'OB-0=%/!;ND4 M@B%L.VED93>K\?0;DYC6*=(01>TPUU-O1&])B' 6A\Q%8E/DTU([A>VF<]9V MVSPRH:PI6*5N^$)NF*DD-[XLX9$-*>UK9'PYD?O/H4L?/S-@2M)9\N7)O?2[ MPC,&'Y%&EIU?RD(7T<3%B0O9"%BQBT6AYB '?K0 A M;D?>*(;XXL!#>+R_/[0N_OC')[.;':"-VOG/N&PN%)%0RVK*.8%$1!$HI!&_ MD49&CO#,NX'/BR*V;LV -6/__VS/X@(?6I[/8L-$>^M:DFN0^^D2/!!)@%;& MT3+8<%/"WA>"%_U.VAB19F,J8-B9BVH[-C)JVY6L0MSO0E]Q/H(L_R(DLK1Z(_I]*_WTT/ MQ=VDT9#6QFLH2IU=E*^@32Y^&#AZA=4F41^9M'H/_OC.5+.&1.13GFA+ 19I M-U^3_+NY:H==Q?V &>NTM8%$O*B@^N8,;A5EF'5[D?F)V43%XP^6+A0[F!!: \+T) MZ_'$ '\.U-BPQ,H"'M3QV'"(*^OYH?,@I6P0.9-%2!76S7DBECL 9,PS@:*K M"M,:O/':U\J3%O3!?V,L!3YT,VM1DGJ;AYBT0I/21F#_B?=6_&Y@ -=VIN43 MWDL 6R241!5(U)\J .SSJ]8%$/G0?^-F0.?)?QS@]K M\"!1,]C[,Z\5P->=/])O.D_\\9UI^,QGJX5,S>?3E*,BD/$9A,:?@>YSLTKJ MXH\G7_=G!D@"NO;>DE(R,,1] _?"N_NS/P]%_+Q1VJ@%-;>.!"Q)Q75(NE'= M_+VX3N9Z=;:D%DE%M8(\:]BYM=E!BL=BZIEAD2:E92$K-4-BS9)%0;>7% M_T9+I%&>1&$@MR/I_I^ 0!87;.>1BVQ)."I;2K2EO-)RBA3JEL6\"?BRK!TI M>H.\75FX:&=I- HY39%LOYH4W%CO2<%L:)24FFTS=AO5A<+C))W/8M%2*6CE M5P&T-\K@/P%!\%X:RV)^):5FLO:75=R>O[)TK0.RE3_0G?QRB@ 1<*EQ6M$LC"WA=XMR9>\0&YWLPEDE#G%+IJU,8'[0KI0O&T? M&+Y8A)C$\[=;=K/2$V_'?<%VW$N>\]T#V)=O\(3U.'K.]M"E686IB50)W*$2 MH)#33/,3#@=U[FP-S!NEC2MV=13QV 4ROJ(T5AT],X*+3$ HO/ ,-,6G/E9 M'NJ%3]/2Q\5!!_'TFY,YH["S+_[WHUG8LD/LM]?29:KYJ1*X$R7PUMA5G,U, M"&0&;[9P<4>4A\- QE>>//4'\KP99C\SL@!I!<6-G"G^V98Z$JGN50H41V-K M%W\\WM\/RMP(&AILDRCY](X@]\/24$-'Y7-U4"J@3L2X!F@\G_E28\*,*(VX(8%IGB2M8- MUH^(-$L+RZ1E%V''D8MX>_Q:KK\);6.DE3G1.IPF9.??WD2:_1HW[XEF QD5 M1RX-,]?OPV_Z^3%-B>QG%';$$6=96]4E'RV/A3%XZ%5. Z.IW#[?_,26[;*5 M3OU-E8 J ;$$: *$U@YEJRG1#"]146@-4+T;B^1**RW]>? 4W&Z M[SP1;XY=B7H'%F)N+[FW")#QE:>@>KV_66ZQ93W2VQ?>2^.LNJ;PZ>A(B[QR M=C ?IMV1F]3$Y3M!K&EU4R6@2J!Y$J"AY1_>I*$EQ7M3 "JA,5]X3@!&-FDG M#Y"?)!%J._+6HD#&-W1MU''\Y=UIG%;EXH<_OSL=ZZ*5UQ&\G%F(S_T".=(A MXX-YX,N (-4.Q@M3/:H2N T)U#Z]#*"8L)15%GZC2*.7$P7KXC5T=O9:D#&-_QR9@&&3]S&C3VR^I MU8&,K^+>XU?8S*/0]^KI-Z? M#0.)>6W[Z+ EZ,>50FH$KCS)-!F0,:+EER) MR#GVR+E,7"]J/1(M7YYZ5"6@2N"7+X$V![)?ODC5%JH24"70UA)0@:RM):Z6 LITI E4"+2T %LA87J9JA*@%5 FTM@?\'B*F>=Z.@G?\ 245.1*Y"8((! end GRAPHIC 10 logoa181a.jpg begin 644 logoa181a.jpg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lfvn-20210201_htm.xml IDEA: XBRL DOCUMENT 0000849146 2020-11-03 2020-11-03 0000849146 false 8-K 2021-02-01 LIFEVANTAGE CORP DE 001-35647 90-0224471 3300 Triumph Blvd Suite 700 Lehi UT 84043 801 432-9000 false false false false Common Stock, par value $0.0001 LFVN NASDAQ false XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover Page
Nov. 03, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 01, 2021
Entity Registrant Name LIFEVANTAGE CORP
Entity Central Index Key 0000849146
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-35647
Entity Tax Identification Number 90-0224471
Entity Address, Address Line One 3300 Triumph Blvd
Entity Address, Address Line Two Suite 700
Entity Address, City or Town Lehi
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84043
City Area Code 801
Local Phone Number 432-9000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol LFVN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.lifevantage.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports lfvn-20210201.htm earningsrelease_q2fy21.htm exhibit992pressrelease.htm lfvn-20210201.xsd lfvn-20210201_cal.xml lfvn-20210201_def.xml lfvn-20210201_lab.xml lfvn-20210201_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lfvn-20210201.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "lfvn-20210201_cal.xml" ] }, "definitionLink": { "local": [ "lfvn-20210201_def.xml" ] }, "inline": { "local": [ "lfvn-20210201.htm" ] }, "labelLink": { "local": [ "lfvn-20210201_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "lfvn-20210201_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "lfvn-20210201.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lfvn", "nsuri": "http://www.lifevantage.com/20210201", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lfvn-20210201.htm", "contextRef": "icdafc6af61ea4d0bba68169cce34f9bf_D20201103-20201103", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.lifevantage.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lfvn-20210201.htm", "contextRef": "icdafc6af61ea4d0bba68169cce34f9bf_D20201103-20201103", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 20 0000849146-21-000032-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000849146-21-000032-xbrl.zip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